BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

iTeos Therapeutics S.A. made several hires Tuesday, including Matthew Gall as CFO and Yvonne McGrath as VP of R&D. Gall was SVP of corporate development at Sarepta Therapeutics Inc. (NASDAQ:SRPT); McGrath was CSO of Complix...
BioCentury | May 1, 2020
Product Development

How the U.K. healthcare sector is leveraging its strengths to beat COVID-19

Crisis is the mother of invention and COVID-19 is no exception. But amid all the gloom are signs of a nascent revolution in how we create and develop new drugs, vaccines and diagnostics. The U.K....
BioCentury | Mar 11, 2020
Deals

‘Disadvantaged’ Gilead flipped partner negotiations into M&A discussion ahead of $4.9B Forty Seven deal

As four companies negotiated for partnerships with Forty Seven around its lead asset, magrolimab, Gilead’s relative commercial weakness in cancer appeared to inspire the company to seek an M&A deal instead, leading to the eventual...
BC Extra | Jul 30, 2019
Financial News

June 30 Financial Quick Takes: $40M series B for Hinova; plus TriArm and PredictImmune raise rounds

Hinova Pharmaceuticals raises $40M series B  Hinova Pharmaceuticals Inc (Chengdu, China) completed a $40 million series B round led by Hermed Capital and Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196), with participation from Lang...
BC Extra | May 13, 2019
Company News

May 13 Company Quick Takes: PeptiDream/JCR, Grail, Lilly, Onconova/HanX, Regeneron

PeptiDream, JCR deal produces drug carriers for CNS delivery  The 2016 partnership between PeptiDream Inc. (Tokyo:4587) and JCR Pharmaceuticals Co. Ltd. (Tokyo:4552) has led to the development of constrained peptides that bind TFRC and are...
BioCentury | Mar 25, 2019
Politics, Policy & Law

Is personalized medicine doomed worldwide if biosimilars fail in the U.S.?

Europe is way ahead of the U.S. in biosimilar approvals and establishing a sustainable competitive marketplace, and it is not clear that the U.S. can even catch up. But over-protecting the U.S. originator market may...
BioCentury | Mar 14, 2019
Politics, Policy & Law

Love it or hate it, the myopic IPI won’t lower Medicare drug prices

The Trump administration has proposed that the U.S. pay similar prices to what companies charge in Europe, starting with drugs covered under Medicare Part B. The administration figures that pegging U.S. prices to an International...
BC Innovations | Feb 12, 2019
Translation in Brief

Stabilizing mutant proteins

A team from Novartis Institutes for BioMedical Research (NIBR) and University of British Columbia has hit upon a strategy for treating diseases caused by loss-of-function protein mutations: target allosteric pockets on the mutant proteins to...
BioCentury | Dec 21, 2018
Product Development

China’s clinical talent gap

While regulatory changes in China have helped clear the way for rapid growth of its clinical trial infrastructure, the country’s dearth of clinical experts could hold back the expansion until new talent is up to...
BC Week In Review | Dec 7, 2018
Financial News

Salubris leads Viracta venture round, gets Chinese rights to cancer therapy

Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) led a series C round for Viracta Therapeutics Inc. (San Diego, Calif.) on Dec. 4 and gained Chinese rights to develop Viracta’s nanatinostat (VRx-3996) in combination with an antiviral...
Items per page:
1 - 10 of 490
BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

iTeos Therapeutics S.A. made several hires Tuesday, including Matthew Gall as CFO and Yvonne McGrath as VP of R&D. Gall was SVP of corporate development at Sarepta Therapeutics Inc. (NASDAQ:SRPT); McGrath was CSO of Complix...
BioCentury | May 1, 2020
Product Development

How the U.K. healthcare sector is leveraging its strengths to beat COVID-19

Crisis is the mother of invention and COVID-19 is no exception. But amid all the gloom are signs of a nascent revolution in how we create and develop new drugs, vaccines and diagnostics. The U.K....
BioCentury | Mar 11, 2020
Deals

‘Disadvantaged’ Gilead flipped partner negotiations into M&A discussion ahead of $4.9B Forty Seven deal

As four companies negotiated for partnerships with Forty Seven around its lead asset, magrolimab, Gilead’s relative commercial weakness in cancer appeared to inspire the company to seek an M&A deal instead, leading to the eventual...
BC Extra | Jul 30, 2019
Financial News

June 30 Financial Quick Takes: $40M series B for Hinova; plus TriArm and PredictImmune raise rounds

Hinova Pharmaceuticals raises $40M series B  Hinova Pharmaceuticals Inc (Chengdu, China) completed a $40 million series B round led by Hermed Capital and Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196), with participation from Lang...
BC Extra | May 13, 2019
Company News

May 13 Company Quick Takes: PeptiDream/JCR, Grail, Lilly, Onconova/HanX, Regeneron

PeptiDream, JCR deal produces drug carriers for CNS delivery  The 2016 partnership between PeptiDream Inc. (Tokyo:4587) and JCR Pharmaceuticals Co. Ltd. (Tokyo:4552) has led to the development of constrained peptides that bind TFRC and are...
BioCentury | Mar 25, 2019
Politics, Policy & Law

Is personalized medicine doomed worldwide if biosimilars fail in the U.S.?

Europe is way ahead of the U.S. in biosimilar approvals and establishing a sustainable competitive marketplace, and it is not clear that the U.S. can even catch up. But over-protecting the U.S. originator market may...
BioCentury | Mar 14, 2019
Politics, Policy & Law

Love it or hate it, the myopic IPI won’t lower Medicare drug prices

The Trump administration has proposed that the U.S. pay similar prices to what companies charge in Europe, starting with drugs covered under Medicare Part B. The administration figures that pegging U.S. prices to an International...
BC Innovations | Feb 12, 2019
Translation in Brief

Stabilizing mutant proteins

A team from Novartis Institutes for BioMedical Research (NIBR) and University of British Columbia has hit upon a strategy for treating diseases caused by loss-of-function protein mutations: target allosteric pockets on the mutant proteins to...
BioCentury | Dec 21, 2018
Product Development

China’s clinical talent gap

While regulatory changes in China have helped clear the way for rapid growth of its clinical trial infrastructure, the country’s dearth of clinical experts could hold back the expansion until new talent is up to...
BC Week In Review | Dec 7, 2018
Financial News

Salubris leads Viracta venture round, gets Chinese rights to cancer therapy

Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) led a series C round for Viracta Therapeutics Inc. (San Diego, Calif.) on Dec. 4 and gained Chinese rights to develop Viracta’s nanatinostat (VRx-3996) in combination with an antiviral...
Items per page:
1 - 10 of 490